Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pegunigalsidase Alfa
Pegunigalsidase alfa is an enzyme replacement used to treat Fabry disease by replacing a missing enzyme that reduces harmful fat buildup.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg University Hospital University Clinic for Pediatrics and Adolescent Medicine
Salzburg, Austria
Centre Hospitalier Universitaire De Bordeaux
Medical Genetics
Bordeaux, France
Centre Hospitalier Universitaire De Montpellier
Pediatric nephrology department
Montpellier, France

Sponsor: Chiesi Farmaceutici S.p.A.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.